IL2 and neoplasm: Further, consistent with the findings obtained in vitro (Fig. 3d and e), the combined treatment of the aptamer and antibody significantly increased the levels of both IL-2 and IFN-γ compared with each single treatment, as assessed by RT-qPCR on tumor samples (Fig. 5f).